Myldamo (Modafinil)

Modafinil, the active ingredient in Myldamo, is a eugeroic (wakefulness‑promoting agent) presented as an oral formulation for oral use. It treats excessive daytime sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work sleep disorder.

GNH USA supplies Myldamo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Modafinil is used to promote wakefulness in sleep‑related disorders.

Narcolepsy: reduces daytime sleep attacks and improves alertness. Obstructive sleep apnea (excessive daytime sleepiness): alleviates residual sleepiness in patients using CPAP. Shift work sleep disorder: helps maintain alertness during scheduled work periods.

Modafinil may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Insomnia: difficulty initiating or maintaining sleep. - Anxiety: heightened nervousness or restlessness. - Dry mouth: reduced salivation. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Severe rash or Stevens‑Johnson syndrome: requires immediate medical attention. - Psychiatric symptoms: emergence of mania, depression, or hallucinations. - Cardiovascular events: hypertension, palpitations, or arrhythmia. - Anaphylaxis: acute allergic reaction with swelling and breathing difficulty. - Hepatic injury: abnormal liver function tests or jaundice.

Before initiating therapy, clinicians should evaluate individual risk factors and monitor for adverse events.

Assess cardiovascular status: evaluate blood pressure and heart disease before starting. Monitor psychiatric history: use cautiously in patients with anxiety, depression, or psychosis. Avoid use in uncontrolled hypertension: may exacerbate blood pressure. Consider renal/hepatic impairment: dose adjustment may be required. Pregnancy and lactation: use only if benefit outweighs risk. Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Modafinil can interact with several drug classes, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole): increase plasma levels of modafinil. - CYP3A4 inducers (e.g., rifampin): decrease modafinil effectiveness. - Oral contraceptives: may reduce hormonal contraceptive efficacy.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): may increase risk of insomnia or anxiety. - Antihypertensives: modafinil may lower blood pressure, requiring dose adjustment.